Clinical Trials
94 trialsNCT05198349 2026-04-22
First in Human Study of M1069 in Advanced Solid Tumors
EMD Serono
Phase 1 Terminated
NCT05694013 2025-10-22
ORIGAMA
Hoffmann-La Roche
Phase 2/3 Terminated
NCT02959437 2025-10-21
Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)
Incyte Corporation
Phase 1/2 Terminated
NCT06790303 2025-06-04
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 2
GlaxoSmithKline
Phase 2 Terminated
NCT04418661 2025-05-29
Safety and Efficacy Study of Vociprotafib (SAR442720) in Combination With Other Agents in Advanced Malignancies
Sanofi
Phase 1/2 Terminated
NCT01369641 2025-05-16
The Effect of Sodium Thiosulfate Eardrops on Hearing Loss in Patients Who Receive Cisplatin Therapy
Thomas Jefferson University
Phase NA Terminated
NCT01871441 2025-05-16
Haploidentical Donor Hematopoietic Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Thomas Jefferson University
Phase 2 Terminated
NCT03752203 2025-03-06
Sodium Fluorescein-Guided Resection of Pediatric Neurosurgical Tumors
University of Colorado, Denver
Phase NA Terminated
NCT05126433 2025-02-28
JAZZ EMERGE201
Jazz Pharmaceuticals
Phase 2 Terminated
NCT00748709 2025-02-11
Phase II Trial of BIBW 2992 (Afatinib) in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification.
Boehringer Ingelheim
Phase 2 Terminated
NCT04812535 2025-02-11
Non-comparative Study of IFX-1 Alone or IFX-1+Pembrolizumab in Patients With Locally Advanced or Metastatic cSCC.
InflaRx GmbH
Phase 2 Terminated
NCT03839940 2025-01-29
MIST
Alliance for Clinical Trials in Oncology
Phase 3 Terminated
NCT03599661 2025-01-09
Developing and Validating Fertilit-e
Wake Forest University Health Sciences
Terminated
NCT04376502 2025-01-03
Immune Checkpoint Inhibitor and MR-guided SBRT for Limited Progressive Metastatic Carcinoma.
Baptist Health South Florida
Phase NA Terminated
NCT03915717 2024-11-26
Observational Study of Outcomes After EchoMark and EchoSure-based Free Flap Monitoring
Sonavex, Inc.
Terminated
NCT04685798 2024-09-19
Optimized Diffusion-Weighted Imaging for the Evaluation of Post-Treatment Squamous Cell Carcinoma in the Neck: Comparative Study With FDG PET/CT
Washington University School of Medicine
Phase NA Terminated
NCT04534283 2024-08-07
A Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib.
Indiana University
Phase 2 Terminated
NCT03387111 2024-08-05
QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed
ImmunityBio, Inc.
Phase 1/2 Terminated
NCT04393454 2024-07-25
Study to Evaluate the Efficacy and Safety of Sirolimus in Subjects With Metastatic, Mismatch Repair Deficient Solid Tumors After Immunotherapy
Albert Einstein College of Medicine
Phase 2 Terminated
NCT03416335 2024-05-30
A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile
Sumitomo Pharma America, Inc.
Phase 1/2 Terminated
NCT04319224 2024-05-30
Vopratelimab (JTX-2011) Alone and in Combination With Anti-Programmed Cell Death Protein 1 (PD-1) or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) in Subjects With Advanced and/or Refractory Solid Tumors
Jounce Therapeutics, Inc.
Phase 1/2 Terminated
NCT04738292 2024-05-03
Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study)
University of Wisconsin, Madison
Phase 2 Terminated
NCT03396471 2024-04-18
Study of Pembrolizumab and Concurrent Radiation in Patients With Previously Treated Carcinoma of Unknown Primary
Hoosier Cancer Research Network
Phase 2 Terminated
NCT04349280 2024-04-18
A Study to Evaluate the Efficacy and Safety of Bintrafusp Alfa (M7824) Monotherapy in Metastatic or Locally Advanced Urothelial Cancer
GlaxoSmithKline
Phase 1 Terminated
NCT01243333 2024-04-17
Multi-Tracer Positron Emission Tomography in Patients With Solid Tumors
University of Utah
Phase NA Terminated
NCT05071183 2024-04-02
A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors
Turning Point Therapeutics, Inc.
Phase 1/2 Terminated
NCT03885908 2024-03-25
Automated Geriatric Co-Management Program in Older Patients With Solid Mass or Nodule Suspicious for Cancer
Memorial Sloan Kettering Cancer Center
Phase NA Terminated
NCT03604445 2024-03-04
This Study Aims to Find and Test a Safe Dose of BI 905677 in Patients With Different Types of Cancer (Solid Tumours)
Boehringer Ingelheim
Phase 1 Terminated
NCT03997448 2024-02-20
Abemaciclib and Pembrolizumab in Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI18-149
Big Ten Cancer Research Consortium
Phase 2 Terminated
NCT01311713 2024-01-30
Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 in Participants With Solid Tumors
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1/2 Terminated
NCT04894994 2023-12-05
FLX475 in Combination With Ipilimumab in Advanced Melanoma
RAPT Therapeutics, Inc.
Phase 2 Terminated
NCT02478320 2023-07-17
Phase II Study of Ilorasertib (ABT348) in Patients With CDKN2A Deficient Solid Tumors
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT03637764 2023-07-10
Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies
Sanofi
Phase 1/2 Terminated
NCT04194528 2023-06-27
S1916 Digital Medicine Program for Pain Control in Cancer Patients
SWOG Cancer Research Network
Phase NA Terminated
NCT02761694 2023-05-06
MK-4440-001
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Phase 1 Terminated
NCT00886782 2023-04-28
A Study of BMS-863233 in Patients With Advanced and/or Metastatic Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Terminated
NCT03251924 2023-02-28
A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Terminated
NCT02213133 2023-01-26
STARRS
Karyopharm Therapeutics Inc
Phase 2 Terminated
NCT02288377 2023-01-18
REMINET
Federation Francophone de Cancerologie Digestive
Phase 2/3 Terminated
NCT02576444 2022-12-28
OLAPCO
Yale University
Phase 2 Terminated
NCT04800627 2022-12-27
Pevonedistat and Pembrolizumab for the Treatment of dMMR/MSI-H Metastatic or Locally Advanced Unresectable Solid Tumor
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT00293215 2022-10-10
Biodistribution Study of CMD-193 in Patients With Advanced Tumours Expressing the Lewis-Y Antigen
Ludwig Institute for Cancer Research
Phase 1 Terminated
NCT04000581 2022-07-22
Impact of Early Mobility on Post-Surgery Recovery in Patients Undergoing Oncologic Surgeries
Roswell Park Cancer Institute
Phase NA Terminated
NCT04003623 2022-05-10
Efficacy and Safety of Pemigatinib in Participants With Solid Tumors With FGFR Mutations or Translocations (FIGHT-208)
Incyte Corporation
Phase 2 Terminated
NCT03000179 2022-04-14
Safety and Efficacy of Avelumab in Small Intestinal Adenocarcinoma
Vanderbilt-Ingram Cancer Center
Phase 2 Terminated
NCT01441115 2021-12-28
ECI301 and Radiation for Advanced or Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT03875859 2021-05-20
Topical Remetinostat Gel as Neoadjuvant Therapy in Patients With Squamous Cell Carcinoma (SCC)
Stanford University
Phase 2 Terminated
NCT02291614 2021-03-16
A Phase 1 Study of AMG 211 in Participants With Advanced Gastrointestinal Cancer
Amgen
Phase 1 Terminated
NCT01206296 2021-03-09
Adjuvant Intraperitoneal Gemcitabine for Resectable Pancreatic Adenocarcinoma
Medstar Health Research Institute
Phase 2 Terminated
NCT03363776 2020-12-19
An Investigational Immuno-Therapy Study of Experimental Medication BMS-986277 Given Alone and in Combination With Nivolumab in Epithelial Cancers
Bristol-Myers Squibb
Phase 1/2 Terminated